As recently written by Cruz and coll., antiphospholipid antibodies (aPL) are frequently found in immune thrombocytopenia (ITP) and are not associated with specific clinical feature [1]. Similarly, thrombocytopenia is frequently reported in APS patients and is one of the most common non-criteria manifestations of the disease. Underlining pathological mechanisms of thrombocytopenia in APS are various, and mostly not related to definite ITP. In the life-threatening variant of APS, called the catastrophic APS (CAPS), thrombocytopenia is due to a thrombotic microangiopathy characterized by the occurrence of thrombosis in multiple organs over a short period of time [2].